{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:22:29Z","timestamp":1772166149056,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004063","name":"Knut och Alice Wallenbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003426","name":"G\u00f6ran Gustafssons Stiftelse f\u00f6r Naturvetenskaplig och Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003426","id-type":"DOI","asserted-by":"publisher"}]},{"name":"swedish heart and lung Foundation"},{"DOI":"10.13039\/501100001862","name":"Svenska Forskningsr\u00e5det Formas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011077","name":"Sk\u00e5nes universitetssjukhus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In rodents, neurotensin contributes to high fat diet induced obesity by facilitation of intestinal fat absorption. The effect of oral lipid load on plasma proneurotensin and relationship with plasma triglycerides in humans is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate the acute effects of an oral lipid load on proneurotensin and plasma triglycerides and their interrelationships in healthy individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting\/ methods<\/jats:title>\n                    <jats:p>Twenty-two healthy subjects were given 150\u2009mL of full milk cream (54\u2009g fat) and 59\u2009mL of pure olive oil (54\u2009g fat) in the fasted state at two different occasions separated by at least 1\u2009week in random order. Venous blood was drawn at fasted before 0\u2009h (h) and at 1\u2009h, 2\u2009h and 4\u2009h after ingestion. Post-ingested values of proneurotensin and plasma triglycerides were compared with fasting levels and post ingestion Area Under the Curve (AUC) of proneurotensin was correlated with that of plasma triglycerides.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      An immediate rise of plasma proneurotensin and plasma triglycerides were observed after ingestion of cream with maximum increase at 2\u2009h for proneurotensin [mean (95% confidence interval)] of 22 (12\u201331) pmol\/L\n                      <jats:italic>(P\u2009&lt;\u20090.001)<\/jats:italic>\n                      and at 3\u2009h for triglycerides of 0.60 (0.43\u20130.78) mmol\/L\n                      <jats:italic>(P\u2009&lt;\u20090.001).<\/jats:italic>\n                      Similarly, plasma proneurotensin and plasma triglycerides increased after ingestion of olive oil with maximum increase of proneurotensin at 3\u2009h of 62 (46\u201378) pmol\/L\n                      <jats:italic>(P\u2009&lt;\u20090.001)<\/jats:italic>\n                      and plasma triglycerides at 3\u2009h of 0.32 (0.18\u20130.45) mmol\/L\n                      <jats:italic>(P\u2009&lt;\u20090.001).<\/jats:italic>\n                      The post lipid load AUC for proneurotensin correlated significantly with the AUC for plasma triglycerides both after cream (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u20090.49,\n                      <jats:italic>P\u2009=\u20090.021<\/jats:italic>\n                      ) and olive oil (\n                      <jats:italic>r<\/jats:italic>\n                      \u00a0=\u20090.55,\n                      <jats:italic>P\u2009=\u20090.008<\/jats:italic>\n                      ), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Proneurotensin increases after an oral lipid load of both cream and olive oil and the rise of post-ingestion plasma triglycerides is significantly related to the rise of post-ingestion proneurotensin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-020-01361-0","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T06:44:32Z","timestamp":1597992272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Magnitude of rise in proneurotensin is related to amount of triglyceride appearance in blood after standardized oral intake of both saturated and unsaturated fat"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7918-5217","authenticated-orcid":false,"given":"Ayesha","family":"Fawad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Struck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Bennet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marju","family":"Orho-Melander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olle","family":"Melander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"issue":"6","key":"1361_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s11886-012-0313-7","volume":"14","author":"I Graham","year":"2012","unstructured":"Graham I, Cooney MT, Bradley D, Dudina A, Reiner Z. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep. 2012;14(6):709\u201320.","journal-title":"Curr Cardiol Rep"},{"issue":"6865","key":"1361_CR2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1038\/414782a","volume":"414","author":"P Zimmet","year":"2001","unstructured":"Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782\u20137.","journal-title":"Nature"},{"issue":"2","key":"1361_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2337\/diacare.22.2.233","volume":"22","author":"M Coutinho","year":"1999","unstructured":"Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22(2):233\u201340.","journal-title":"Diabetes Care"},{"key":"1361_CR4","doi-asserted-by":"publisher","unstructured":"Beverly JK, Budoff MJ. Atherosclerosis: Pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation. J Diab. 2020;12(2):102\u20134. https:\/\/doi.org\/10.1111\/1753-0407.12970.","DOI":"10.1111\/1753-0407.12970"},{"issue":"1","key":"1361_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11892-009-0088-4","volume":"10","author":"B Enkhmaa","year":"2010","unstructured":"Enkhmaa B, Ozturk Z, Anuurad E, Berglund L. Postprandial lipoproteins and cardiovascular disease risk in diabetes mellitus. Curr Diabetes Rep. 2010;10(1):61\u20139.","journal-title":"Curr Diabetes Rep"},{"issue":"4","key":"1361_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/nu10040526","volume":"10","author":"I Barchetta","year":"2018","unstructured":"Barchetta I, Cimini FA, Capoccia D, Bertoccini L, Ceccarelli V, Chiappetta C, Leonetti F, Di Cristofano C, Silecchia G, Orho-Melander M, et al. Neurotensin is a lipid-induced gastrointestinal peptide associated with visceral adipose tissue inflammation in obesity. Nutrients. 2018;10(4):526.","journal-title":"Nutrients"},{"issue":"1\u20133","key":"1361_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0167-0115(00)00183-X","volume":"93","author":"BM Tyler-McMahon","year":"2000","unstructured":"Tyler-McMahon BM, Boules M, Richelson E. Neurotensin: peptide for the next millennium. Regul Pept. 2000;93(1\u20133):125\u201336.","journal-title":"Regul Pept"},{"issue":"2","key":"1361_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0006-8993(83)90576-0","volume":"272","author":"M Goedert","year":"1983","unstructured":"Goedert M, Emson PC. The regional distribution of neurotensin-like immunoreactivity in central and peripheral tissues of the cat. Brain Res. 1983;272(2):291\u20137.","journal-title":"Brain Res"},{"issue":"7603","key":"1361_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nature17662","volume":"533","author":"J Li","year":"2016","unstructured":"Li J, Song J, Zaytseva YY, Liu Y, Rychahou P, Jiang K, Starr ME, Kim JT, Harris JW, Yiannikouris FB, et al. An obligatory role for neurotensin in high-fat-diet-induced obesity. Nature. 2016;533(7603):411\u20135.","journal-title":"Nature"},{"key":"1361_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.1982.tb31557.x","volume":"400","author":"SE Leeman","year":"1982","unstructured":"Leeman SE, Carraway RE. Neurotensin: discovery, isolation, characterization, synthesis and possible physiological roles. Ann N Y Acad Sci. 1982;400:1\u201316.","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"1361_CR11","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1210\/jc.2017-02751","volume":"103","author":"I Barchetta","year":"2018","unstructured":"Barchetta I, Cimini FA, Leonetti F, Capoccia D, Di Cristofano C, Silecchia G, Orho-Melander M, Melander O, Cavallo MG. Increased plasma Proneurotensin levels identify NAFLD in adults with and without type 2 diabetes. J Clin Endocrinol Metab. 2018;103(6):2253\u201360.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1361_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jhep.2014.08.030","volume":"62","author":"L Rabinowich","year":"2015","unstructured":"Rabinowich L, Fishman S, Hubel E, Thurm T, Park WJ, Pewzner-Jung Y, Saroha A, Erez N, Halpern Z, Futerman AH, et al. Sortilin deficiency improves the metabolic phenotype and reduces hepatic steatosis of mice subjected to diet-induced obesity. J Hepatol. 2015;62(1):175\u201381.","journal-title":"J Hepatol"},{"issue":"6","key":"1361_CR13","doi-asserted-by":"publisher","first-page":"G1413","DOI":"10.1152\/ajpgi.2001.281.6.G1413","volume":"281","author":"X Gui","year":"2001","unstructured":"Gui X, Dobner PR, Carraway RE. Endogenous neurotensin facilitates enterohepatic bile acid circulation by enhancing intestinal uptake in rats. Am J Physiol Gastrointest Liver Physiol. 2001;281(6):G1413\u201322.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"14","key":"1361_CR14","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1001\/jama.2012.12998","volume":"308","author":"O Melander","year":"2012","unstructured":"Melander O, Maisel AS, Almgren P, Manjer J, Belting M, Hedblad B, Engstrom G, Kilger U, Nilsson P, Bergmann A, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. Jama. 2012;308(14):1469\u201375.","journal-title":"Jama"},{"issue":"7","key":"1361_CR15","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.peptides.2006.01.021","volume":"27","author":"A Ernst","year":"2006","unstructured":"Ernst A, Hellmich S, Bergmann A. Proneurotensin 1-117, a stable neurotensin precursor fragment identified in human circulation. Peptides. 2006;27(7):1787\u201393.","journal-title":"Peptides"},{"issue":"4","key":"1361_CR16","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/clinchem\/20.4.470","volume":"20","author":"CC Allain","year":"1974","unstructured":"Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470\u20135.","journal-title":"Clin Chem"},{"issue":"6","key":"1361_CR17","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem"},{"key":"1361_CR18","first-page":"205","volume-title":"Radioimmunoassay and related techniques","author":"J Thorell","year":"1978","unstructured":"Thorell J, Larson SM. Radioimmunoassay and related techniques. ST Louis: The CV Mosby Company; 1978. p. 205\u201311."},{"issue":"5","key":"1361_CR19","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1210\/jc.2017-02424","volume":"103","author":"A Fawad","year":"2018","unstructured":"Fawad A, Bergmann A, Struck J, Nilsson PM, Orho-Melander M, Melander O. Proneurotensin predicts cardiovascular disease in an elderly population. J Clin Endocrinol Metab. 2018;103(5):1940\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1361_CR20","doi-asserted-by":"publisher","first-page":"13640","DOI":"10.1038\/s41598-019-50040-3","volume":"9","author":"A Fawad","year":"2019","unstructured":"Fawad A, Nilsson PM, Struck J, Bergmann A, Melander O, Bennet L. The association between plasma proneurotensin and glucose regulation is modified by country of birth. Sci Rep. 2019;9(1):13640.","journal-title":"Sci Rep"},{"issue":"3","key":"1361_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.298.3.309","volume":"298","author":"S Bansal","year":"2007","unstructured":"Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Jama. 2007;298(3):309\u201316.","journal-title":"Jama"},{"issue":"3","key":"1361_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1046\/j.1463-1326.2003.00264.x","volume":"5","author":"L Samuelsson","year":"2003","unstructured":"Samuelsson L, Gotts\u00e4ter A, Lindg\u00e4rde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes Obes Metab. 2003;5(3):195\u2013201.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1361_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1463-1326.2004.00467.x","volume":"7","author":"BA Swinburn","year":"2005","unstructured":"Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID. Effect of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab. 2005;7(3):254\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1361_CR24","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1053\/j.gastro.2017.12.024","volume":"154","author":"R Khera","year":"2018","unstructured":"Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, Berry JD, Camilleri M, Singh S. Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis. Gastroenterology. 2018;154(5):1309\u201319 e1307.","journal-title":"Gastroenterology"},{"issue":"1","key":"1361_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1210\/en.2015-1600","volume":"157","author":"KV Grunddal","year":"2016","unstructured":"Grunddal KV, Ratner CF, Svendsen B, Sommer F, Engelstoft MS, Madsen AN, Pedersen J, N\u00f8hr MK, Egerod KL, Nawrocki AR, et al. Neurotensin is Coexpressed, Coreleased, and acts together with GLP-1 and PYY in Enteroendocrine control of metabolism. Endocrinology. 2016;157(1):176\u201394.","journal-title":"Endocrinology"},{"issue":"215","key":"1361_CR26","first-page":"298","volume":"36","author":"The Helsinki Declaration of the World Medical Association (WMA)","year":"2014","unstructured":"The Helsinki Declaration of the World Medical Association (WMA). Ethical principles of medical research involving human subjects. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2014;36(215):298\u2013301.","journal-title":"Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-020-01361-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01361-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T19:14:44Z","timestamp":1629486884000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-020-01361-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1186\/s12944-020-01361-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-20122\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-20122\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-20122\/v3","asserted-by":"object"}]},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"assertion":[{"value":"28 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The investigation confirms to the principles outlined in the Declaration of Helsinki [\n                      \n                      ]. The Ethics Committee at Lund University approved the study and all participants have provided written informed consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The data does not include any individual personal data including individual details, images or videos and hence consent for publication is not applicable in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS is employed by Sphingotec GmbH, a company having patent rights in the proneurotensin assay and commercializing it. AB is CEO of Sphingotec GmbH and holds shares in this company. The other authors declare that they have neither disclosures nor financial or non-financial competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}